M&A

News

EQRx's low-price drugs mission ends with Revolution buy

EQRx's pledge to disrupt the pharma pricing system started with a clarion call in 2020 but ended with a whimper today with an agreement to be taken over by Revolution Medi

News

After cutbacks, Biogen adds new drug with $7.3bn Reata buy

Biogen has turned to M&A to offset its recent troubles with pipeline failures and aborted product launches, agreeing to a $7.3 billion deal to acquire Reata Pharma.

News

AZ builds in genomic medicine with $1bn Pfizer deal

AstraZeneca's rare diseases unit Alexion has agreed to pay $1 billion to acquire Pfizer's early-stage gene therapy pipeline and enabling technologies - the company's first

News

Chris Cargill, Sosei Heptares chief executive

Sosei snaps up Idorsia’s Japan, Korea units in $466m deal

Japan’s Sosei Group has completed a transition to a commercial-stage pharmaceutical company after buying rights to an already-marketed drug and a pipeline of experimental

News

Big Health buys teen depression DTx developer Limbix

In another example of consolidation in the digital therapeutics (DTx) category, Big Health has agreed to buy Limbix, adding its app for adolescents and young adults with s

News

FTC asks for more info on Pfizer’s $43bn Seagen takeover

The US Federal Trade Commission (FTC) has asked for more information on Pfizer’s $43 billion agreement to acquire Seagen before it will deliver a decision on whether the d

EQRx's low-price drugs mission ends with Revolution buy

After cutbacks, Biogen adds new drug with $7.3bn Reata buy

AZ builds in genomic medicine with $1bn Pfizer deal

Sosei snaps up Idorsia’s Japan, Korea units in $466m deal

Big Health buys teen depression DTx developer Limbix

FTC asks for more info on Pfizer’s $43bn Seagen takeover

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

M&A

Editor's Picks